Mirae Asset Global Investments Co. Ltd. Makes New $18.23 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 73,867 shares of the biopharmaceutical company’s stock, valued at approximately $18,226,000. Mirae Asset Global Investments Co. Ltd. owned 0.06% of Alnylam Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Toth Financial Advisory Corp acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at $25,000. Keating Financial Advisory Services Inc. acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $42,000. Burkett Financial Services LLC acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth about $37,000. CoreCap Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 744.4% during the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 134 shares during the period. Finally, Ascentis Independent Advisors bought a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $64,000. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of several research analyst reports. Citigroup cut their target price on Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating on the stock in a research report on Wednesday, October 14th. Truist Financial downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the stock from $315.00 to $225.00 in a report on Monday. Cantor Fitzgerald reissued a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 30th. Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating on the stock in a report on Friday, October 30th. Finally, Stifel Nicolaus cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 price target on the stock. in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $305.86.

Insider Buying and Selling

In related news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by insiders.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam plans to present five-year HELIOS-B results and additional clinical and real-world evidence on AMVUTTRA (vutrisiran) at conferences in November. The presentations could provide new information about the treatment’s potential, though the announcement did not include new study results. Alnylam conference presentation announcement
• Negative Sentiment: Analyst sentiment weakened: Raymond James cut its rating from Strong Buy to Outperform, while Bernstein moved from Outperform to Market Perform. Raymond James downgrade Bernstein downgrade
• Negative Sentiment: Price expectations have also been trimmed: the consensus target fell 13.64% to $325.18, and Truist lowered its target to $225 from $315 while cutting its rating to Hold. Although the targets remain above the share price cited in the reports, the reductions signal increased caution. Consensus target reduction

Alnylam Pharmaceuticals Trading Up 1.2%

ALNY opened at $159.89 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $156.00 and a 1-year high of $479.79. The company has a current ratio of 2.48, a quick ratio of 2.43 and a debt-to-equity ratio of 0.18. The company has a market cap of $21.42 billion, a P/E ratio of 8.30 and a beta of 0.42. The company has a fifty day moving average price of $233.41 and a two-hundred day moving average price of $284.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating the consensus estimate of $1.66 by $14.60. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.90 earnings per share. Analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.58 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.